Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Prurigo Nodularis Treatment Market Snapshot (2023 to 2033)

The anticipated size of the prurigo nodularis treatment market in 2022 was US$ 671.4 million and is estimated to be US$ 693.3 million in 2023. Various non-government organizations with the help of different funding mechanisms, have led to transitional projects which help in enabling an ample amount of financing for the research and development of the market.

Different initiatives like activities and programs have been undertaken for growth in awareness about rare diseases with their available therapeutic options which in turn boosted the demand for prurigo nodularis treatment. According to Future Market Insights Report, the prurigo nodularis treatment market is projected to expand at a CAGR of 3.0% between 2023 and 2033, totaling around US$ 930.9 million by 2033.

The Prurigo nodularis treatment market is experiencing growth due to the rising demand for orphan drugs for the treatment of rare diseases like Prurigo nodularis. Several non-governmental organizations are collaborating with diverse funding mechanisms to facilitate transitional projects that provide adequate financing for research and development in the market.

Various initiatives like awareness activities and programs are expected to increase knowledge about rare diseases and available therapeutic options, thereby driving the demand for prurigo nodularis treatment.

Demand for innovative drugs and preventative therapies to improve patient outcomes is increasing due to the expanding patient population and limited availability of biologics, drugs, and devices for associated disorders. Further, the market for prurigo nodularis therapeutics is anticipated to benefit from the increasing research and development investments aimed at developing orphan drugs for rare health conditions.

The usage of photochemotherapy, cryotherapy, and immunosuppressants for managing prurigo nodularis disease is further expected to propel the market growth during the forecast period.

Attribute Details
Projected Forecast Value (2022) US$ 671.4 million
Projected Forecast Value (2023) US$ 693.3 million
Projected Forecast Value (2033) US$ 930.9 million
Growth rate 3.0% CAGR
Forecast period 2023 to 2033

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Prurigo Nodularis Treatment Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 To 2033)

The global prurigo nodularis treatment market grew at a CAGR of 2.8% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 3.0% between 2023 and 2033.

The market for prurigo nodularis treatment benefits from a diverse range of available options, including both topical and oral medications. Patients and healthcare providers can choose from multiple treatment options that suit their specific needs. Ongoing research, such as the development of monoclonal antibodies and other biologic therapies, holds promise for improving patient outcomes.

Advancements in medical technology have led to the introduction of new and innovative treatment options, such as advanced phototherapy methods, providing patients with many choices.

The usage of emollients to treat prurigo nodularis is expected to generate new growth opportunities for the market in the coming years. Emollients offer numerous benefits, including their ability to effectively soothe and heal dry skin. Further, the increase in the prevalence of prurigo nodularis has led to a high demand for effective medications that provide better and quick outcomes. These medications are particularly helpful in improving the appearance and health of the skin, thereby driving the demand for these drugs.

Flexible and easy regulatory guidelines governing the use of orphan drugs for treating prurigo nodularis are expected to shape the demand outlook for treatment drugs during the forecast period. With their well-established supply chain activities for cross-border trading, retail pharmacies are the primary distribution channel for supplying drugs for managing prurigo nodularis disorder which is expected to drive market growth in the forthcoming years further. Moreover, increasing adoption of e-commerce, online pharmacies are expected to witness significant growth which is further expected to fuel market growth in the forthcoming years.

What are the Prominent Drivers of the Prurigo Nodularis Treatment Market?

Innovations in New Treatment Options to Drive Market Growth

The rising prevalence of conditions like prurigo nodularis and bacterial infections, coupled with an increase in patients, is expected to drive market growth. Key market players are primarily focusing on the population aged between 20 to 60 years, as well as patients with human immune deficiency virus and atopic dermatitis since they are susceptible to these diseases.

An increase in awareness about treatment options among the population is likely to drive market growth. Additionally, various innovations in the field of treatment are also expected to create new opportunities for market expansion. Further, regulatory bodies are continuously striving to create favorable outcomes for the development and commercialization of orphan drugs for patients with rare diseases. Such regulations help accelerate the development and approval process of investigational drugs.

Increasing Demand for Capsaicin Cream is Fueling the Market Growth

Burgeoning demand for capsaicin cream is further anticipated to propel market growth. Capsaicin cream is estimated to account for a significant share of the global market among different drug classes during the projection period as there is increasing demand for topical drugs that are easy to apply and highly effective. Consequently, increasing demand for capsaicin cream is thus expected to contribute to the growth of the prurigo nodularis treatment market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Key Challenges of the Prurigo Nodularis Treatment Market?

Lack of Awareness about the Disease to Restrain Market Expansion

The dearth of awareness about rare diseases like prurigo nodularis and the available treatment options is expected to hinder the market growth. Poor economic conditions and healthcare infrastructure in some countries impede the adoption of prurigo nodularis treatment. Further, market growth is limited due to the heavy reliance of emerging economies on developed nations for raw materials, skilled labor, advanced technology therapeutics, and drugs.

Region-Wise Insights

What is the Growth Outlook in Germany?

Germany Driving Growth with a Significant CAGR

Europe prurigo nodularis treatment market accounted for a revenue share of 58.6% in 2022. Germany is expected to dominate the regional market by expanding at a CAGR of 5.1% during the forecast period. The dominant position of Germany in the market can be attributed to the presence of leading market players and significant government-led research and development initiatives in the region.

How is United Kingdom Said to Hold a Market Position in the Market?

Rising Rate of Approval and Commercialization of Drugs in the United Kingdom

The United Kingdom is said to hold a profitable market during the forecast period, driven by the increasing prevalence of prurigo nodularis disorder in the region expanding at a CAGR of 2.1% in the market. Moreover, the increasing rate of approval and commercialization of drugs for prurigo nodularis treatment in this region is expected to fuel market growth. The majority of key players have their headquarters based in the United Kingdom, which is expected to induce growth in the region.

How is the Prurigo Nodularis Market Faring in the United States?

The rise in Awareness among Health Professionals is Driving Growth in the United States

North America’s prurigo nodularis market accounted for a revenue share of 14.9% in 2022. The United States alone accounted for a revenue share of 13.7% in the same year. Market growth in this region can be attributed to various factors such as:

  • The rising incidence of the condition
  • Increasing awareness among healthcare professionals and patients
  • Improved diagnostic rates
  • Robust healthcare infrastructure
  • Development of new treatment options
  • A preference for topical treatments
  • Increasing investment in research and development activities

How is Japan Contributing to its Growth in the Market?

Presence of Developed Healthcare Industries

Japan is considered to be among the most developed nations which has the presence of various developed healthcare industries that might help in the immediate treatment of prurigo nodularis thus raising the share of the market with a value of 4.0%

What is the Impact of the Indian Market on the Prurigo Nodularis Treatment Market?

Feasible Costs for the Prurigo Nodularis Treatment in India Market

Prurigo Nodularis Treatment in India is considered to be a great choice as the cost of treatment of such a disorder is reasonable in India and people can easily cure it within a proper period, thus raising the market at a CAGR of 3.5%

Why is China Considered to Have a Leading Position in the Market?

Economic Growth Helps China to Hold a Leading Position in the Market

Growth in the economy for prurigo nodularis treatment has led to colossal growth in China market at a CAGR of 3.6%

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Comparative Analysis of the Prurigo Nodularis Treatment Market

Prurigo Nodularis Treatment Market:

Attributes Prurigo Nodularis Treatment Market
CAGR (2023 to 2033) 3.0%
Market Value 2023 US$ 693.3 million
Growth Factor Growth in the awareness of rare diseases and the availability of therapeutic options are expected to uplift the demand for prurigo nodularis treatment.
Future Opportunities Easy and flexible guidelines for orphan drugs used in the treatment of prurigo nodularis are expected to boost the demand for the prurigo nodularis treatment market.
Market trends Non-government organizations with different funding mechanisms are led for transitional projects enabling maximum financing for the research and development of the market.

DNA/RNA Extraction Market:

Attributes DNA/RNA Extraction Market
CAGR (2023 to 2033) 7.4%
Market Value 2023 US$ 1.40 billion
Growth Factor An increase in research and development has led to growth in the market.
Future Opportunities Next-generation DNA extraction kits offer significant growth opportunities for the global DNA/RNA extraction market.
Market trends Technological advancements in DNA/RNA extraction kits are anticipated to grow the market.

Construction Aggregates Market:

Attributes Construction Aggregates Market
CAGR (2023 to 2033) 4.86%
Market Value 2023 US$ 397.67 million
Growth Factor Development of infrastructural projects for rapid urbanization might drive the market growth.
Future Opportunities Need for offices, residential premises, etc. might raise the supply of building aggregates worldwide.
Market trends Rapid construction in emerging economies might drive the market in the future.

Category wise Insights

Which Drug Class is Said to Hold a Dominant Position in the Market?

Capsaicin Cream to Dominate the Market with a Sizable Share

The capsaicin cream segment dominated the prurigo nodularis treatment market by accounting for a revenue share of 40.34% in 2022.

Capsaicin creams serve as a topical remedy for alleviating primary symptoms related to prurigo nodularis. By reducing the activity of pain-related nerve cells in the skin, topical ointment helps alleviate pain in patients suffering from this skin condition.

Increase the popularity of capsaicin in treating prurigo nodularis which may help in driving the growth of the segment. The lack of effective targeted therapy for the disease is further expected to drive gains in this segment during the forecast period.

Which Distribution Channel is Expected to Dominate the Market?

Retail Pharmacies Leading the Market with a Significant CAGR

Retail pharmacies accounted for a revenue share of 53.10% in 2022, in the prurigo nodularis treatment market.

Growth of the segment is being driven by the increasing preference for obtaining medications from retail pharmacies. Oral or topical medications are the primary treatment option for patients suffering from prurigo nodularis, with surgical procedures being reserved for cases where they are necessary. As a result, patients prefer to obtain their medications from retail pharmacies, which also offer discounts on various medications, further contributing to market growth.

Patients find retail pharmacies to be easily accessible and a convenient option for purchasing their prescribed medications. Unlike specialty pharmacies, patients do not have to wait for their medications to be delivered. They can simply walk into a retail pharmacy and fill their prescription on the spot.

Patients suffering from prurigo nodularis can find a wide range of medications, including corticosteroids, antihistamines, and other topical treatments, at their local retail pharmacy. Competitive pricing offered by retail pharmacies is an added advantage, particularly for patients without health insurance coverage or high deductibles. These factors are expected to propel growth in retail pharmacies in the prurigo nodularis therapeutics market.

Competitive Landscape

Some of the prominent players in the global market

  • Bayer AG
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Celgene Corporation
  • Galderma SA (Nestle Skin Health Company)
  • VYNE Therapeutics Inc.

Some of the important developments of the key players in the market are:

  • In June 2023, Novartis announced that it has agreed to acquire Chinook Therapeutics, a Seattle, WA, based clinical-stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases where the agreed deal, is subject to customary closing conditions and is fully in line with Novartis strategy to focus on innovative medicines and will significantly expand its renal portfolio, complementing the existing pipeline.
  • In February 2023, Pfizer has an unprecedented number of launches with the company expecting to have 19 new products in the next 18 months.

Report Scope

Attribute Details
Growth Rate CAGR of 3.0% from 2023 to 2033
Market value in 2023 US$ 693.3 million
Market value in 2033 US$ 930.9 million
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units US$ million for Value and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • By Country
  • By Drug Class
  • By Distribution Channel
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East & Africa
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • China
  • Japan
  • South Korea
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • Rest of Asia Pacific
  • GCC countries
  • South Africa
  • Israel
  • Rest of the Middle East and Africa
Key Companies Profiled
  • Bayer AG
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Celgene Corporation
  • Galderma SA (Nestle Skin Health Company)
  • VYNE Therapeutics Inc.
Customisation Scope Available on Request

Key Segmentation

By Drug Class:

  • Corticosteroids
    • Topical
    • Oral
    • Emollients
    • Capsaicin Cream
    • Antihistamines
    • Anticonvulsants
    • Antidepressants
    • Neurokinin 1 Receptor (NK1R)
    • Opiate Receptor Antagonists
    • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East & Africa

Frequently Asked Questions

How Big Will the Market be in the North America by 2033?

The North America market may generate a maximum revenue by 2033.

Which Country is Set to Register Exponential Growth in Market?

The United States, the United Kingdom, and Germany may witness significant growth in the market.

What Drives Sales of Prurigo Nodularis Treatment?

The growing awareness and better treatment options are expected to drive sales.

What Key Trends are Driving the Market Growth?

Rising research and development may drive market growth over the coming years.

How was the Historical Performance of the Market?

The market recorded a CAGR of 2.8% in 2022.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Corticosteroids

            5.3.1.1. Topical

            5.3.1.2. Oral

            5.3.1.3. Emollients

            5.3.1.4. Capsaicin Cream

            5.3.1.5. Antihistamines

            5.3.1.6. Anticonvulsants

            5.3.1.7. Antidepressants

            5.3.1.8. Neurokinin 1 Receptor (NK1R)

            5.3.1.9. Opiate Receptor Antagonists

            5.3.1.10. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Online Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. The USA

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Distribution Channel

    15.6. United Kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Distribution Channel

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Distribution Channel

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Distribution Channel

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Distribution Channel

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Distribution Channel

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Distribution Channel

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Distribution Channel

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Distribution Channel

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Distribution Channel

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Distribution Channel

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Distribution Channel

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Distribution Channel

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Drug Class

            15.21.2.2. By Distribution Channel

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Drug Class

            15.22.2.2. By Distribution Channel

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Drug Class

            15.23.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Bayer AG

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Pfizer Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. GlaxoSmithKline Plc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Teva Pharmaceutical Industries Ltd.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Johnson & Johnson

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Merck & Co. Inc.

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Sanofi SA

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Takeda Pharmaceutical Company Limited

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Novartis AG

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Celgene Corporation

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Galderma SA (Nestle Skin Health Company)

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. VYNE Therapeutics Inc.

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 12: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 47: Western Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 55: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Western Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 59: Western Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 74: Eastern Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 76: South Asia and Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: South Asia and Pacific Market Attractiveness by Drug Class, 2023 to 2033

Figure 89: South Asia and Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 91: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 92: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 93: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 98: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 100: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 101: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 103: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 104: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 105: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 106: Middle East and Africa Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 107: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 118: Middle East and Africa Market Attractiveness by Drug Class, 2023 to 2033

Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Atopic Dermatitis Treatment Market

Published : January 2024

Consumer Product

Skin Care Devices Market

Published : March 2023

Healthcare

Allergy Diagnostics Market

Published : December 2022

Healthcare

Skin Replacement Market

Published : June 2022

Explore Healthcare Insights

View Reports

Prurigo Nodularis Treatment Market